(Q33385795)

English

Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512). (English)

1 reference

Europe PubMed Central

26 July 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

author name string

My Merl

1

1 reference

Europe PubMed Central

26 July 2017

Cj Hoimes

2

1 reference

Europe PubMed Central

26 July 2017

T Pham

3

1 reference

Europe PubMed Central

26 July 2017

M Wasif Saif

4

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

1 September 2009

1 reference

Europe PubMed Central

26 July 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

26 July 2017

18

1 reference

Europe PubMed Central

26 July 2017

9

1 reference

Europe PubMed Central

26 July 2017

1257-1264

1 reference

Europe PubMed Central

26 July 2017

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1517%2F13543780903136724

21 January 2018

Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543780903136724

21 January 2018

Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?

1 reference

https://api.crossref.org/works/10.1517%2F13543780903136724

21 January 2018

Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients

1 reference

https://api.crossref.org/works/10.1517%2F13543780903136724

21 January 2018

Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial

1 reference

https://api.crossref.org/works/10.1517%2F13543780903136724

21 January 2018

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1517%2F13543780903136724

21 January 2018

Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation

1 reference

https://api.crossref.org/works/10.1517%2F13543780903136724

21 January 2018

Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study

1 reference

https://api.crossref.org/works/10.1517%2F13543780903136724

21 January 2018

Identifiers

10.1517/13543780903136724

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33385795&oldid=1574777594"